Greek COPD study tracks Real-World switch to triple inhaler

NCT ID NCT05915182

Completed Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Mar 31, 2026 · Last updated May 13, 2026 · Updated 5 times

Summary

This study followed 212 adults with moderate to severe COPD in Greece who were prescribed a triple-combination inhaler (Trixeo Aerosphere). Researchers recorded why doctors switched from dual therapy to triple therapy and measured changes in patients' breathing symptoms and quality of life over 52 weeks. The goal was to gather real-world evidence, not to test a new treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY DISEASE, CHRONIC OBSTRUCTIVE (COPD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site

Alexandroupoli, 68100, Greece
Research Site

Athens, 11521, Greece
Research Site

Athens, 11527, Greece
Research Site

Athens, 12462, Greece
Research Site

Athens, 17562, Greece
Research Site

Corfu, 49100, Greece
Research Site

Crete, 71409, Greece
Research Site

Crete, 71500, Greece
Research Site

Crete, 73300, Greece
Research Site

Ioannina, 45500, Greece
Research Site

Larissa, 41110, Greece
Research Site

Pátrai, 26332, Greece
Research Site

Pátrai, 26504, Greece
Research Site

Thessaloniki, 56429, Greece
Research Site

Thessaloniki, 57010, Greece

Conditions

Explore the condition pages connected to this study.

PULMONARY DISEASE, CHRONIC OBSTRUCTIVE (COPD)